← 治験一覧に戻る
阻害因子を有する重症血友病AおよびB患者におけるフィツシラン（ALN-AT3SC）の研究
基本情報
- NCT ID
- NCT03417102
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 60
- 治験依頼者名
- Sanofi
概要
The purpose of this study was to determine the frequency of bleeding episodes in participants receiving fitusiran as prophylactic treatment of hemophilia compared to participants who were assigned to continue with their regular medication. In addition, the study assessed safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).
対象疾患
Hemophilia AHemophilia B
介入
fitusiran(DRUG)
Bypassing agents(DRUG)
依頼者（Sponsor）
Genzyme, A Sanofi Company(INDUSTRY)